Close Menu

NEW YORK – Celsius Therapeutics said Wednesday that it has signed collaboration agreements with the University of Oxford in the UK, the Cleveland Clinic in the US, and LMU University Hospital Munich in Germany to apply single-cell analytics technology to research into inflammatory bowel disease.

The Cambridge, Massachusetts-based vendor will lend its proprietary single-cell genomics platform and machine-learning technology to analyze longitudinal biopsies at three different stages.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Imperial College London researchers are shifting away from testing a COVID-19 vaccine to focus on combating newly emerging SARS-CoV-2 variants, the Independent says.

According to the Associated Press, genetic genealogy has helped law enforcement officials identify an unknown victim of the Green River Killer.

In PNAS this week: target to reduce chemotherapy-induced cardiac injury, tool finds ancient endogenous RNA viruses, and more.

Moderna reports its vaccine is effective against new SARS-CoV-2 strains, though it is also developing a booster, according to the New York Times.